StockData

AC Immune vs Immunome

ACIU and IMNM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ACIU and IMNM compare

Immunome grew revenue faster over the last twelve months (−63.3% versus −86.9% for AC Immune).

Immunome scores higher on the StockData Score (7 against 3 for AC Immune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricACIUIMNM
Size and price
Market cap–$2.0B
Share price$2.11$17.18
Change, 1 year−35.9%0.23%
Change, 5 years−59.2%1.2%
Beta (5Y)0.211.62
Employees122177
StockData Score
Total score37 (better)
Valuation score00
Growth score00
Performance score01 (better)
Health score36 (better)
Dividend score00
Valuation
P/S–486×
P/B–3.3×
FCF yield–−10.5%
Growth
Revenue growth (TTM)−86.9%−63.3% (better)
Revenue growth, 5Y average−25.4%–
Profitability
Operating margin−1940% (better)−5948%
Net margin–−5594%
FCF margin−1964% (better)−5119%
Return on equity–−50.1%
Financial health
Debt / equity–0.00
Interest coverage−362.9×–
Current ratio0.9321.68 (better)
Altman Z-score–35.70
Piotroski F-score–4
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–104%
Held by insiders4.4%6.4%
Insider net buying, 12 months−$27.9K (better)−$25.2M
Short interest, % of float–15.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.